Covid-19 roundup: J&J be­gins piv­otal Phase III tri­al for vac­cine; Con­tro­ver­sial hu­man chal­lenge tri­als to be­gin in Lon­don — re­port

John­son & John­son an­nounced it’s be­gin­ning a piv­otal Phase III tri­al for its Covid-19 can­di­date, JNJ-78436735 — the first sin­gle-dose vac­cine in this stage.

The Phase III tri­al, dubbed EN­SEM­BLE, will en­roll 60,000 pa­tients world­wide, mak­ing it the largest Phase III study of a Covid-19 vac­cine to date. J&J said the can­di­date achieved pos­i­tive in­ter­im re­sults in a Phase I/IIa study, which will be pub­lished “im­mi­nent­ly.” There’s a pos­si­bil­i­ty that the first batch­es will be ready for po­ten­tial emer­gency use in ear­ly 2021, ac­cord­ing to the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.